Thymosin alpha 1 for use in treatment of cystic fibrosis
Granted: September 10, 2024
Patent Number:
12083165
The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
Treatment of cancer with alpha thymosin peptide and PD-1 inhibitors
Granted: February 7, 2023
Patent Number:
11571465
The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or…
Thymosin alpha 1 for use in treatment of cystic fibrosis
Granted: December 13, 2022
Patent Number:
11524056
The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
Thymosin alpha 1 for use in treatment of cystic fibrosis
Granted: November 19, 2019
Patent Number:
10478474
The present invention concerns Thymosin alpha 1 for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
Treatment of cancer with immune stimulators
Granted: August 8, 2017
Patent Number:
9724395
The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or…
Alpha thymosin peptides as vaccine enhancers
Granted: May 6, 2014
Patent Number:
8716012
The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer…
Treatment of infections with alpha thymosin peptides
Granted: March 5, 2013
Patent Number:
8389680
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
Treatment of infections with alpha thymosin peptides
Granted: June 26, 2012
Patent Number:
8207294
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
Granted: June 5, 2012
Patent Number:
8193152
An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
Treatment of melanoma
Granted: April 24, 2012
Patent Number:
8163702
An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.
Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
Granted: October 4, 2011
Patent Number:
8029799
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
Granted: September 13, 2011
Patent Number:
8017129
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
Granted: March 15, 2011
Patent Number:
7906486
An immunomodulatory compound is utilized to treat mucosa disease.
Methods of protecting against radiation damage using alpha thymosin
Granted: March 1, 2011
Patent Number:
7897567
Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.
Thymosin alpha 1 peptide/polymer conjugates
Granted: November 20, 2007
Patent Number:
7297676
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in…
Treatment of hepatitis C with thymosin and peptide combination therapy
Granted: April 24, 2007
Patent Number:
7208167
A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.
Treatment of tuberculosis using immunomodulator compounds
Granted: February 6, 2007
Patent Number:
7173013
Tuberculosis in an animal is treated by administration of a therapeutically effective amount of an immunomodulator of formula A. In formula (A), n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative. The animal may be a mammal such as a human
Combination therapy method for treating chronic hepatitis B
Granted: December 17, 2002
Patent Number:
6495521
The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which are effective in inhibiting DNA synthesis or DNA polymerase during replication of the hepatitis B virus.
Method of reducing side effects of chemotherapy in cancer patients
Granted: October 8, 2002
Patent Number:
6462017
A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin &agr;1 in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.
Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
Granted: September 11, 2001
Patent Number:
6288033
A method of treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral-effective amount of thymosin alpha 1 (T&agr;1), an antiviral-effective amount of lamivudine, and optionally an antiviral-effective amount of famciclovir is disclosed.
